Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 4/20 | 0.52 |
| ▸ | EDNRA | P25101 | 4/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9065280 | 1.00 | EDNRB (0.52) | EDNRBEDNRABRD4NPSR1KDM4E | |
| SCHEMBL30637685 | 0.84 | EDNRB (0.59) | EDNRBEDNRANPSR1ALDH1A1TSHR | |
| SCHEMBL7222597 | 0.82 | EDNRB (0.61) | EDNRBEDNRABRD4NPSR1KDM4E | |
| SCHEMBL7228577 | 0.82 | EDNRB (0.61) | EDNRBEDNRANPSR1ALDH1A1 | |
| SCHEMBL9063934 | 0.82 | EDNRB (0.61) | EDNRBEDNRABRD4NPSR1KDM4E | |
| SCHEMBL8473746 | 0.81 | PTGS2 (0.58) | EDNRBEDNRABRD4NPSR1ALDH1A1 | |
| SCHEMBL28724738 | 0.75 | KMT2A (0.64) | EDNRBEDNRABRD4NPSR1KDM4E | |
| SCHEMBL6151621 | 0.74 | EDNRB (0.64) | EDNRBEDNRAALDH1A1TSHRMAPK1 | |
| SCHEMBL6150962 | 0.74 | TSHR (0.58) | EDNRBEDNRAALDH1A1TSHRMAPK1 | |
| SCHEMBL7342871 | 0.74 | EDNRB (0.64) | EDNRBEDNRAALDH1A1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6376523-B1 | HYPOTENSIVE AGENTS; ANTIINFLAMMATORY AGENTS; ENDOGENOUS VASOCONSTRUCTION PEPTIDE | TEXAS BIOTECHNOLOGY CORPORATION | 2002-04-23 | — | — | US | claimed |
| US-20010036958-A1 | Benzenesulfonamides and the use thereof to modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS, INC. | 2001-11-01 | — | — | US | claimed |
| EP-1069114-A2 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-01-17 | — | — | EP | claimed |
| EP-0870764-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-10-14 | — | — | EP | claimed |
| US-5514691-A | N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin | IMMUNOPHARMACEUTICS, INC. (US) | 1996-05-07 | — | — | US | claimed |
| EP-0699191-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-03-06 | — | — | EP | claimed |
| WO-1994027979-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | IMMUNOPHARMACEUTICS, INC. (US) | 1994-12-08 | — | — | WO | claimed |
| US-6541498-B2 | Antiinflammatory agents, antiasthmatics | TEXAS BIOTECHNOLOGY | 2003-04-01 | — | — | US | disclosed |
| US-6376523-B1 | HYPOTENSIVE AGENTS; ANTIINFLAMMATORY AGENTS; ENDOGENOUS VASOCONSTRUCTION PEPTIDE | TEXAS BIOTECHNOLOGY CORPORATION | 2002-04-23 | — | — | US | disclosed |
| US-20010036958-A1 | Benzenesulfonamides and the use thereof to modulate the activity of endothelin | ENCYSIVE PHARMACEUTICALS, INC. | 2001-11-01 | — | — | US | disclosed |
| EP-1069114-A2 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-01-17 | — | — | EP | disclosed |
| US-6030991-A | ADJUSTING THE BINDING OF AN ENDOTHELIN PEPTIDE TO ENDOTHELIN A OR, PARTICULARLY, ENDOTHELIN B RECEPTORS, I.E. INHIBITING OR STIMULATING; ANTIINFLAMMATORY AGENT; ASTHMA; KIDNEYS; GASTROINTESTINAL, CARDIOASCULAR DISORDERS; HYPOTENSIVE AGENTS | TEXAS BIOTECHNOLOGY CORP. (US) | 2000-02-29 | — | — | US | disclosed |
| EP-0870764-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-10-14 | — | — | EP | disclosed |
| US-5571821-A | CARDIOVASCULAR DISORDERS TO MODULATE ENDOTHELIN, HYPOTENSIVE AGENTS AND VASOCONSTRICTION | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-11-05 | — | — | US | disclosed |
| US-5514691-A | N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin | IMMUNOPHARMACEUTICS, INC. (US) | 1996-05-07 | — | — | US | disclosed |
| EP-0699191-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994027979-A1 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | IMMUNOPHARMACEUTICS, INC. (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036958-A1 | Benzenesulfonamides and the use thereof to modulate the activity of endothelin | EDNRB, EDNRA, ECE1 | EDNRB 1/4885EDNRA 2/4885BRD4 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.